Analyst Yigal Nochomovitz of Citi maintained a Buy rating on ACADIA Pharmaceuticals, retaining the price target of $33.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yigal Nochomovitz has given his Buy rating due to a combination of factors that highlight ACADIA Pharmaceuticals’ strong financial performance and strategic initiatives. The company continues to generate robust cash flows, which supports its investment in growth opportunities. Notably, ACADIA’s management has shown effective execution, achieving total revenue of approximately $279 million, aligning closely with expectations. This performance is underpinned by a 5% quarter-over-quarter increase in net sales for both Nuplazid and Daybue, with plans to expand Nuplazid’s customer-facing field force by 30% in early 2026.
Furthermore, ACADIA is advancing its pipeline with the initiation of the Phase 2 trial for ACP-204, a next-generation treatment, in Lewy Body Dementia Psychosis. The company is also progressing with its international efforts, including a Phase 3 trial in Japan and an upcoming decision from the Committee for Medicinal Products for Human Use in the EU. These strategic moves, coupled with the anticipation of a significant value inflection point in mid-2026 with the Phase 2 topline readout for ACP-204 in Alzheimer’s Disease Psychosis, contribute to the positive outlook and expected share price return of 47.8%.
According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 5.3% and a 41.72% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Summit Therapeutics, and Lexicon Pharmaceuticals.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $32.00 price target.